Our Company

A Heritage of Improving Lives Through Innovation

History Timeline Top Banner
O

ur company’s legacy of innovation began in 1858, when our founders made it their mission to bring better health solutions to patients who needed them most. Today, we are continuing that tradition by using the latest science and technology to help improve lives through the research and development of new medicines for serious diseases.  See our timeline below for select historical events.

The Journey Begins

EA4C17
EDWARD ROBINSON SQUIBB
1845
EDWARD ROBINSON SQUIBB

EDWARD ROBINSON SQUIBB

Dr. Squibb graduates from Philadelphia’s Jefferson Medical College. He spends a decade as a surgeon in the U.S. Navy, an experience that impresses upon him the urgent need for high-quality, standardized medicines. 

1858

FIRST LABORATORY

Dr. Squibb rents a brownstone in Brooklyn, New York, for his new business and begins pharmaceutical manufacturing operations. In December, he is severely burned in an ether fire that nearly destroys his business.

1858
FIRST LABORATORY

FIRST LABORATORY

Dr. Squibb rents a brownstone in Brooklyn, New York, for his new business and begins pharmaceutical manufacturing operations. In December, he is severely burned in an ether fire that nearly destroys his business.

SQUIBB MEDICINE CHEST
1861–1865
SQUIBB MEDICINE CHEST

SQUIBB MEDICINE CHEST

During the Civil War, Squibb manufactures compact, portable chests for military surgeons that contain an array of medicines and equipment—from ether and morphine to bandages and sponges. Each chest costs about $100, the equivalent of several thousand dollars today. 

 

 

1879

DR. SQUIBB’S PROPOSAL FOR SAFE MEDICINE

Dr. Squibb presents a report to the New York State Medical Society, “Proposed Law to Prevent the Adulteration of Food and Medicine and to Create a State Board of Health.” Known as the Squibb Bill, it becomes law and serves as the basis for the Federal Pure Food and Drug Act of 1906. 

1879
DR. SQUIBB’S PROPOSAL FOR SAFE MEDICINE

DR. SQUIBB’S PROPOSAL FOR SAFE MEDICINE

Dr. Squibb presents a report to the New York State Medical Society, “Proposed Law to Prevent the Adulteration of Food and Medicine and to Create a State Board of Health.” Known as the Squibb Bill, it becomes law and serves as the basis for the Federal Pure Food and Drug Act of 1906. 

CLINTON PHARMACEUTICALS
1887
CLINTON PHARMACEUTICALS

CLINTON PHARMACEUTICALS

William Bristol and John Myers invest $5,000 to purchase the failing Clinton Pharmaceutical Company. With a pledge to sell no “quack remedies,” the two quickly turn the business around.

1892

E.R. SQUIBB & SONS FORMED

Dr. Squibb forms a partnership with his sons, Edward and Charles, and the firm is renamed E.R Squibb & Sons. The company has capital assets of $1.5 million, according to the Articles of Incorporation filed in 1895. 

1892
E.R. SQUIBB & SONS FORMED

E.R. SQUIBB & SONS FORMED

Dr. Squibb forms a partnership with his sons, Edward and Charles, and the firm is renamed E.R Squibb & Sons. The company has capital assets of $1.5 million, according to the Articles of Incorporation filed in 1895. 

FIRST BREAKTHROUGH PRODUCT

1898

FIRST BREAKTHROUGH PRODUCT

Marketed as a tonic and laxative, Sal Hepatica salts, dubbed the “poor man’s spa,” mimic the taste and effect of the natural mineral waters of a Bohemian spa. Within a decade, annual sales rise to a half-million dollars. The product is a mainstay of Bristol-Myers until 1974. 

1898
FIRST BREAKTHROUGH PRODUCT

FIRST BREAKTHROUGH PRODUCT

Marketed as a tonic and laxative, Sal Hepatica salts, dubbed the “poor man’s spa,” mimic the taste and effect of the natural mineral waters of a Bohemian spa. Within a decade, annual sales rise to a half-million dollars. The product is a mainstay of Bristol-Myers until 1974. 

BRISTOL, MYERS COMPANY
1899
BRISTOL, MYERS COMPANY

BRISTOL, MYERS COMPANY

Bristol and Myers rename their business the Bristol, Myers Company, which outgrows its home in Clinton, New York. The company relocates — first to Syracuse and then, in 1899, to Brooklyn to better serve customers in New England and Pennsylvania.

IPANA

1901

IPANA

Bristol-Myers introduces Ipana toothpaste, featuring a disinfectant to prevent tooth decay and gum disease. 

1901
IPANA

IPANA

Bristol-Myers introduces Ipana toothpaste, featuring a disinfectant to prevent tooth decay and gum disease. 

1902

SQUIBB QUALITY-CONTROL LABORATORY

E.R. Squibb & Sons establishes its first quality-control laboratory. Soon, it has nearly 100 employees and produces over 800 preparations. 

1902
SQUIBB QUALITY-CONTROL LABORATORY

SQUIBB QUALITY-CONTROL LABORATORY

E.R. Squibb & Sons establishes its first quality-control laboratory. Soon, it has nearly 100 employees and produces over 800 preparations. 

NEW JERSEY PLANT
1905
NEW JERSEY PLANT

NEW JERSEY PLANT

E.R. Squibb & Sons purchases an ether manufacturing plant in what was then the wilds of New Brunswick, New Jersey. 

1906

PURE FOOD AND DRUG ACT

President Theodore Roosevelt signs the Pure Food and Drug Act of 1906 into law. Although Dr. Squibb died in 1900, the act is a triumph of his lifelong crusade for safe, reliable pharmaceutical products. 

GROWING IN NEW JERSEY

Bristol-Myers purchases seven acres in Hillside, New Jersey, for expanded production of Sal Hepatica. 

1906
PURE FOOD AND DRUG ACT

PURE FOOD AND DRUG ACT

President Theodore Roosevelt signs the Pure Food and Drug Act of 1906 into law. Although Dr. Squibb died in 1900, the act is a triumph of his lifelong crusade for safe, reliable pharmaceutical products. 

GROWING IN NEW JERSEY

Bristol-Myers purchases seven acres in Hillside, New Jersey, for expanded production of Sal Hepatica. 

DIGITALIS

1917

DIGITALIS

E.R. Squibb & Sons pioneers the standardization of digitalis, derived from the foxglove plant as an early treatment for heart conditions.

1917
DIGITALIS

DIGITALIS

E.R. Squibb & Sons pioneers the standardization of digitalis, derived from the foxglove plant as an early treatment for heart conditions.

BRISTOL-MYERS GOES PUBLIC
1929
BRISTOL-MYERS GOES PUBLIC

BRISTOL-MYERS GOES PUBLIC

Gross profits top $1 million and the company’s products are sold in 26 countries. Bristol-Myers becomes a publicly held firm on the New York Stock Exchange. 

1938

SQUIBB INSTITUTE FOR MEDICAL RESEARCH

Squibb furthered its commitment to innovative research by opening the 52,000-square foot Squibb Institute for Medical Research in New Brunswick, New Jersey.

1938
SQUIBB INSTITUTE FOR MEDICAL RESEARCH

SQUIBB INSTITUTE FOR MEDICAL RESEARCH

Squibb furthered its commitment to innovative research by opening the 52,000-square foot Squibb Institute for Medical Research in New Brunswick, New Jersey.

INTOCOSTRIN

1939

INTOCOSTRIN

Squibb researchers develop a new method for preparing curare and provide free samples of Intocostrin to clinical researchers, who find the curare extract helpful in relaxing the muscles of surgical patients.

1939
INTOCOSTRIN

INTOCOSTRIN

Squibb researchers develop a new method for preparing curare and provide free samples of Intocostrin to clinical researchers, who find the curare extract helpful in relaxing the muscles of surgical patients.

CHEPLIN BIOLOGICAL LABORATORIES
1943
CHEPLIN BIOLOGICAL LABORATORIES

CHEPLIN BIOLOGICAL LABORATORIES 

Bristol-Myers acquires Cheplin Laboratories in Syracuse, New York, enabling it to mass produce penicillin during World War II. This marks the company’s entry into ethical drug development. 

1944

PENICILLIN PRODUCTION PLANT

Squibb opens the world’s largest penicillin production facility in New Brunswick, New Jersey.

1944
PENICILLIN PRODUCTION PLANT

PENICILLIN PRODUCTION PLANT

Squibb opens the world’s largest penicillin production facility in New Brunswick, New Jersey.

FLO-CILLIN ‘96’

1948

FLO-CILLIN ‘96’

Bristol Laboratories introduces Flo-Cillin 96, a long-lasting injectable penicillin.

NEW PAIN RELIEVER

Bufferin is also introduced.

1948
FLO-CILLIN ‘96’

FLO-CILLIN ‘96’

Bristol Laboratories introduces Flo-Cillin 96, a long-lasting injectable penicillin.

NEW PAIN RELIEVER

Bufferin is also introduced.

SQUIBB RECEIVES THE LASKER AWARD

1955

SQUIBB RECEIVES THE LASKER AWARD

The company receives one of the most respected science prizes in the world for discovering anti-tubercular properties for an antibiotic used to treat tuberculosis.

1955
SQUIBB RECEIVES THE LASKER AWARD

SQUIBB RECEIVES THE LASKER AWARD

The company receives one of the most respected science prizes in the world for discovering anti-tubercular properties for an antibiotic used to treat tuberculosis.

EARLY CANCER RESEARCH
1956
EARLY CANCER RESEARCH

EARLY CANCER RESEARCH

Bristol-Myers enters the cancer drug development field, building on collaborations around promising antibiotics with the Microbial Chemistry Research Foundation of Japan.

1959

CLAIROL PURCHASED

Bristol-Myers acquires the hair-coloring company Clairol, which was founded in 1931 by Joan and Lawrence M. Gelb. Their son, Richard L. Gelb, would later serve as Bristol-Myers’ president, CEO and Chairman of the Board.

1959
CLAIROL PURCHASED

CLAIROL PURCHASED

Bristol-Myers acquires the hair-coloring company Clairol, which was founded in 1931 by Joan and Lawrence M. Gelb. Their son, Richard L. Gelb, would later serve as Bristol-Myers’ president, CEO and Chairman of the Board.

NEW LABORATORY
1966
NEW LABORATORY

NEW LABORATORY

Ground is broken for the construction of Bristol-Myers Products research and development laboratories in Hillside, New Jersey. It is the largest proprietary laboratory in the world.

1967

MEAD JOHNSON & COMPANY

Bristol-Myers Squibb acquires Mead Johnson. At the time, Mead-Johnson produces the only comprehensive line of infant feeding needs.

1967
MEAD JOHNSON & COMPANY

MEAD JOHNSON & COMPANY

Bristol-Myers Squibb acquires Mead Johnson. At the time, Mead-Johnson produces the only comprehensive line of infant feeding needs.

1967

Anti-Cancer Treatment

Squibb researchers develop the company’s first anti-cancer treatment. 

1967

Anti-Cancer Treatment

Squibb researchers develop the company’s first anti-cancer treatment. 

SQUIBB HEADQUARTERS ESTABLISHED
1971
SQUIBB HEADQUARTERS ESTABLISHED

SQUIBB HEADQUARTERS ESTABLISHED

Squibb establishes worldwide headquarters in Princeton, New Jersey, and expands facilities for the Squibb Institute for Medical Research. This allows Squibb to make more groundbreaking discoveries and advancements.

1972

PALOMAR PICTURES INTERNATIONAL

Bristol-Myers announces the formation of Palomar Pictures International. Palomar produces several films, including The Stepford Wives and The Taking of Pelham One Two Three. The company exits the film business two years later.

1972
PALOMAR PICTURES INTERNATIONAL

PALOMAR PICTURES INTERNATIONAL

Bristol-Myers announces the formation of Palomar Pictures International. Palomar produces several films, including The Stepford Wives and The Taking of Pelham One Two Three. The company exits the film business two years later.

1973

PRODUCT APPROVAL

FDA approves MUTAMYCIN® (mytomycin). 

1973

PRODUCT APPROVAL

FDA approves MUTAMYCIN® (mytomycin). 

1974

PRODUCT APPROVAL

FDA approves BLENOXANE® (bleomycin sulfate). 

1974

PRODUCT APPROVAL

FDA approves BLENOXANE® (bleomycin sulfate). 

1975

PRODUCT APPROVAL

FDA approves CAPOTEN® (captopril). 

1975

PRODUCT APPROVAL

FDA approves CAPOTEN® (captopril). 

1976

PRODUCT APPROVAL

FDA approves CeeNU® (lomustine) and BICNU® (carmustine). 

1976

PRODUCT APPROVAL

FDA approves CeeNU® (lomustine) and BICNU® (carmustine). 

CREATION OF CONVATEC
1978
CREATION OF CONVATEC

CREATION OF CONVATEC

ConvaTec is formed by Squibb to market ostomy and wound therapy products.

1979

PRODUCT APPROVAL

PLATINOL® (cisplatin) becomes the first platinum-containing anti-cancer drug for testicular cancer. 

1979

PRODUCT APPROVAL

PLATINOL® (cisplatin) becomes the first platinum-containing anti-cancer drug for testicular cancer. 

1983

PRODUCT APPROVAL

The FDA approves VEPESID® (etoposide). 

1983

PRODUCT APPROVAL

The FDA approves VEPESID® (etoposide). 

BRISTOL-MYERS RESEARCH COMPLEX OPENS

1986

BRISTOL-MYERS RESEARCH COMPLEX OPENS

Bristol-Myers opens a state-of-the-art research complex in Wallingford, Connecticut, housing more than 800 scientists and support staff. In 1995, it is named the Richard L. Gelb Center for Pharmaceutical Research and Development after the former chairman and CEO. 

1986
BRISTOL-MYERS RESEARCH COMPLEX OPENS

BRISTOL-MYERS RESEARCH COMPLEX OPENS

Bristol-Myers opens a state-of-the-art research complex in Wallingford, Connecticut, housing more than 800 scientists and support staff. In 1995, it is named the Richard L. Gelb Center for Pharmaceutical Research and Development after the former chairman and CEO. 

1986

PRODUCT APPROVAL

BUSPAR, discovered by Bristol-Myers neuroscience researchers, is approved for the treatment of generalized anxiety disorder.

1986

PRODUCT APPROVAL

BUSPAR, discovered by Bristol-Myers neuroscience researchers, is approved for the treatment of generalized anxiety disorder.

1989

BRISTOL-MYERS AND SQUIBB MERGE

Bristol-Myers merges with Squibb, creating a global leader in the health care industry. The merger creates Bristol-Myers Squibb, the world’s second-largest pharmaceutical enterprise. One of the first medicines the new company introduces is PARAPLATIN, approved for treating recurrent ovarian cancer.

1989
BRISTOL-MYERS AND SQUIBB MERGE

BRISTOL-MYERS AND SQUIBB MERGE

Bristol-Myers merges with Squibb, creating a global leader in the health care industry. The merger creates Bristol-Myers Squibb, the world’s second-largest pharmaceutical enterprise. One of the first medicines the new company introduces is PARAPLATIN, approved for treating recurrent ovarian cancer.

BRISTOL-MYERS SQUIBB FOUNDATION ESTABLISHED
1990
BRISTOL-MYERS SQUIBB FOUNDATION ESTABLISHED

BRISTOL-MYERS SQUIBB FOUNDATION ESTABLISHED

Inspired by the Bristol-Myers Fund established in 1953, the Bristol-Myers Squibb Foundation is created to promote health equity and improve health outcomes of populations disproportionately affected by serious diseases. Through its work around the globe, the Foundation focuses on strengthening health care worker capacity, integrating medical care and community-based supportive services, and mobilizing communities in the fight against disease.

1991

Product Approval

1991

Product Approval

1997

RESEARCH CAMPUS OPENS

Bristol-Myers Squibb opens a 433-acre research campus in Hopewell, New Jersey.  

1997
RESEARCH CAMPUS OPENS

RESEARCH CAMPUS OPENS

Bristol-Myers Squibb opens a 433-acre research campus in Hopewell, New Jersey.  

1997

PRODUCT APPROVAL 

1997

PRODUCT APPROVAL 

NATIONAL MEDAL OF TECHNOLOGY
1998
NATIONAL MEDAL OF TECHNOLOGY

NATIONAL MEDAL OF TECHNOLOGY

President Bill Clinton awards the National Medal of Technology — America’s highest honor for technological innovation — to Bristol-Myers Squibb "for extending and enhancing human life through innovative pharmaceutical research and development, and for redefining the science of clinical study through groundbreaking and hugely complex clinical trials that are recognized models in the industry." 

1999

SECURE THE FUTURE INITIATIVE ANNOUNCED

The Bristol-Myers Squibb Foundation announces SECURE THE FUTURE®, a $100 million commitment to advance HIV/AIDS research and community outreach programs in seven African countries: Botswana, Namibia, Lesotho, Swaziland, Uganda, Burkina Faso and Tanzania. 

1999
SECURE THE FUTURE INITIATIVE ANNOUNCED

SECURE THE FUTURE INITIATIVE ANNOUNCED

The Bristol-Myers Squibb Foundation announces SECURE THE FUTURE®, a $100 million commitment to advance HIV/AIDS research and community outreach programs in seven African countries: Botswana, Namibia, Lesotho, Swaziland, Uganda, Burkina Faso and Tanzania. 

CHILDREN’S HOSPITAL OPENS
2001
CHILDREN’S HOSPITAL OPENS

CHILDREN’S HOSPITAL OPENS

The Bristol-Myers Squibb Children’s Hospital opens as part of Robert Wood Johnson University Hospital in New Brunswick, New Jersey. The first freestanding children’s hospital in the state, it offers care without regard to a family’s ability to pay and offers more than 45 pediatric specialties.

DUPONT PHARMACEUTICALS PURCHASED 

DuPont pharmaceuticals is acquired, strengthening Bristol-Myers Squibb’s HIV and cardiovascular businesses while also adding medical imaging. 

2001

PRODUCT ACQUISITION   

2001

PRODUCT ACQUISITION   

2002

PRODUCT APPROVAL

FDA approves ABILIFY® (aripiprazole). 

2002

PRODUCT APPROVAL

FDA approves ABILIFY® (aripiprazole). 

2003

PRODUCT APPROVAL

FDA approves REYATAZ® (atazanavir).

2003

PRODUCT APPROVAL

2004

PRODUCT APPROVAL

FDA approves BARACLUDE® (entecavir).
U.S. Full Prescribing Information including Boxed WARNINGS  (PDF)

FDA approves ERBITUX® (cetuximab). 

2004

PRODUCT APPROVAL

CLINICAL CENTER FOR CHILDREN WITH HIV/AIDS

2007

CLINICAL CENTER FOR CHILDREN WITH HIV/AIDS OPENS

The clinical center at the Bristol-Myers Squibb Children’s Hospital at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, is dedicated to the research and treatment of children’s immune system disorders and infectious diseases. The Bristol-Myers Squibb Pediatric Infectious Disease and Immunology Center is made possible by a $5 million gift from the Bristol-Myers Squibb Foundation.

2007
CLINICAL CENTER FOR CHILDREN WITH HIV/AIDS

CLINICAL CENTER FOR CHILDREN WITH HIV/AIDS OPENS

The clinical center at the Bristol-Myers Squibb Children’s Hospital at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, is dedicated to the research and treatment of children’s immune system disorders and infectious diseases. The Bristol-Myers Squibb Pediatric Infectious Disease and Immunology Center is made possible by a $5 million gift from the Bristol-Myers Squibb Foundation.

2007

PRODUCT APPROVAL

FDA approves IXEMPRA® (ixabepilone).

2007

PRODUCT APPROVAL

FDA approves IXEMPRA® (ixabepilone).

2009

BRISTOL-MYERS SQUIBB ACQUIRES MEDAREX

Bristol-Myers Squibb acquires Medarex, Inc., a biotech company and a partner since 2005. The acquisition significantly expands the company’s oncology and immunology pipeline.

2009
BRISTOL-MYERS SQUIBB ACQUIRES MEDAREX

BRISTOL-MYERS SQUIBB ACQUIRES MEDAREX

Bristol-Myers Squibb acquires Medarex, Inc., a biotech company and a partner since 2005. The acquisition significantly expands the company’s oncology and immunology pipeline.

2009

PRODUCT APPROVAL

FDA approves ONGLYZA® (saxagliptin).

2009

PRODUCT APPROVAL

FDA approves ONGLYZA® (saxagliptin).

2010

PRODUCT APPROVAL

FDA approves KOMBIGLYZE® XR (saxagliptin and metformin HCl extended‐release).

2010

PRODUCT APPROVAL

FDA approves KOMBIGLYZE® XR (saxagliptin and metformin HCl extended‐release).

INVESTING IN THE FUTURE
2013
INVESTING IN THE FUTURE

INVESTING IN THE FUTURE

To expand its capabilities in development and manufacturing of biologics, the company announces a $250 million expansion of its manufacturing complex in Devens, Massachusetts.

EXPANSION CONTINUES

2014

EXPANSION CONTINUES

Construction begins on a new, large-scale biologics manufacturing facility in Cruiserath, Ireland, to be built on the grounds of its existing bulk pharmaceutical manufacturing plant.

A new state-of-the-art office campus is planned for Lawrenceville, New Jersey, to replace leased facilities in Plainsboro and West Windsor. 

2014
EXPANSION CONTINUES

EXPANSION CONTINUES

Construction begins on a new, large-scale biologics manufacturing facility in Cruiserath, Ireland, to be built on the grounds of its existing bulk pharmaceutical manufacturing plant.

A new state-of-the-art office campus is planned for Lawrenceville, New Jersey, to replace leased facilities in Plainsboro and West Windsor. 

2014

Product Approval

FDA approves OPDIVO® (nivolumab).

2014

Product Approval

2015

BRISTOL-MYERS SQUIBB NAMED A LEADING SUSTAINABLE COMPANY

Bristol-Myers Squibb is recognized as one of Dow Jones’ North America Index of Leading Sustainable Companies. Its efforts to promote economic, social and environmental sustainability are core to the mission and reflect its ongoing commitment to patients, employees and partners, the environment and communities around the world.

Bristol-Myers Squibb Foundation Celebrates 60th Anniversary 

The Bristol-Myers Squibb Foundation marks a quarter of a century helping millions of people across the world overcome serious diseases. 

2015
BRISTOL-MYERS SQUIBB NAMED A LEADING SUSTAINABLE COMPANY

BRISTOL-MYERS SQUIBB NAMED A LEADING SUSTAINABLE COMPANY

Bristol-Myers Squibb is recognized as one of Dow Jones’ North America Index of Leading Sustainable Companies. Its efforts to promote economic, social and environmental sustainability are core to the mission and reflect its ongoing commitment to patients, employees and partners, the environment and communities around the world.

Bristol-Myers Squibb Foundation Celebrates 60th Anniversary 

The Bristol-Myers Squibb Foundation marks a quarter of a century helping millions of people across the world overcome serious diseases. 

2015

PRODUCT APPROVAL

2015

PRODUCT APPROVAL

PRINCETON PIKE CAMPUS OPENS
2016
PRINCETON PIKE CAMPUS OPENS

PRINCETON PIKE CAMPUS OPENS

This state-of-the-art campus in New Jersey features work space designed to foster greater innovation, productivity and collaboration. 

PRIX GALIEN AWARD

Bristol-Myers Squibb is awarded the Prix Galien U.S. “Discovery of the Decade.” This is the third Prix Galien honor that the company has received, after being recognized for “Best Biotechnology Product” in 2012 and “Best Biotechnology Product” in 2015. 

BRISTOL-MYERS SQUIBB CELEBRATES 130TH ANNIVERSARY

2017

BRISTOL-MYERS SQUIBB CELEBRATES 130TH ANNIVERSARY 

Chairman and CEO Giovanni Caforio rings the New York Stock Exchange’s Closing Bell in celebration of the company milestone. 

2017
BRISTOL-MYERS SQUIBB CELEBRATES 130TH ANNIVERSARY

BRISTOL-MYERS SQUIBB CELEBRATES 130TH ANNIVERSARY 

Chairman and CEO Giovanni Caforio rings the New York Stock Exchange’s Closing Bell in celebration of the company milestone.